In announcing the Q2 2018 results, Takeda Pharmaceuticals CEO Christopher Weber announced that his group still has various non-core assets to sell in order to fund the GBP46bn acquisition of Shire.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,